Intellia Therapeutics, Inc.
NTLA
$9.21
$0.57036.60%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
1/7/2025
-
MarketBeat
5/2/2025
-
Tickeron - Technical Analysis
5/2/2025
-
MarketBeat
5/1/2025
-
Zacks Investment Research
5/1/2025
-
Zacks Investment Research
5/1/2025
-
Globe Newswire
5/1/2025
-
MarketBeat
4/30/2025
-
MarketBeat
4/30/2025
-
Fool.com Headlines
4/29/2025
-
Zacks Investment Research
4/29/2025
-
Finbold Stock News
4/28/2025
-
MarketBeat
4/27/2025
-
MarketBeat
4/26/2025
-
Benzinga
4/25/2025
-
MarketBeat
4/23/2025
-
MarketBeat
4/23/2025
-
GuruFocus
4/23/2025
-
PR Newswire
4/23/2025
-
MarketBeat
Intellia Therapeutics (NTLA, $7.92) price may drop as it broke higher Bollinger Band on Apr 21, 2025
4/22/2025
-
Tickeron - Stocks
4/22/2025
-
MarketBeat
4/21/2025
-
GuruFocus
4/21/2025
-
Seeking Alpha - Healthcare
4/21/2025
-
SeekingAlpha.com: All News
4/21/2025
-
Ticker Report
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, February 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
857 285 6200
Address
40 Erie Street
Cambridge, MA 02139
Cambridge, MA 02139
Country
Year Founded
Business Description
Sector
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in...
more